{"filings":[{"id":1700399,"accession_number":"0001213900-26-078887","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-07-17T01:50:00+00:00","items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Jasper Therapeutics acquires Kira Pharmaceuticals; issues ~9.8M shares and raises $132M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Jasper issued ~5.2M common shares and ~4.6M convertible preferred shares to Kira shareholders; Kira holders own ~88.73% of pro forma common pre-PIPE.","Concurrent $132M PIPE from sale of ~4.7M preferred shares (convertible into 61 common each) to new investors; closing expected July 20, 2026.","Pre-merger Jasper shareholders receive one CVR per share entitling to pro rata share of $30M if FDA issues Priority Review Voucher for briquilimab by Dec 31, 2028.","Kira subsidiary entered Mirador License Agreement for anti-C5a assets; $12M upfront, up to $458.5M milestones, low-to-mid single-digit royalties.","Board changes: Vishal Kapoor and Scott Brun resigned; Patrick Crutcher appointed director; Matthew Ros appointed COO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1694036,"accession_number":"0001213900-26-078781","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-07-16T21:15:34+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jasper Therapeutics completes all-stock acquisition of Kira Pharmaceuticals and $132M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Jasper acquires Kira in all-stock deal; pre-deal Jasper holders own ~6.68%, Kira holders ~49.86%, PIPE investors ~43.46% of combined company.","Concurrent $132M private placement co-led by Affinity Asset Advisors and Ikarian Capital; expected to close July 20, 2026.","Kira out-licenses KP-301 and KP-402 to Mirador Therapeutics for $12M upfront plus potential milestones.","Combined company cash runway through H2 2028; key milestones include KP-104 Phase 2 renal data in Q4 2026 and end-of-Phase 2 FDA meeting for PNH in H1 2027.","Briquilimab pre-BLA meeting for SCID expected in Q1 2027; KP-701 IND/CTA filing in Q1 2027 with first-in-human data in Q3 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":945400,"accession_number":"0001213900-26-066782","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-06-09T20:05:24+00:00","items":["3.01"],"status":"ready","headline":"Jasper Therapeutics receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On June 3, 2026, Nasdaq notified Jasper that its common stock bid price closed below $1.00 for 30 consecutive business days.","Company has until November 30, 2026 to regain compliance by achieving $1.00+ close for at least 10 consecutive days.","If not cured by Nov 30, Jasper may qualify for an additional 180-day period subject to other listing standards and potential reverse stock split.","Failure to cure could result in delisting of common stock and warrants from Nasdaq Capital Market.","Jasper intends to monitor bid price and consider options including a reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":759717,"accession_number":"0001213900-26-063157","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-06-01T12:01:20+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jasper Therapeutics initiates strategic review including potential sale or wind-down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board of Directors initiates comprehensive review of strategic alternatives to maximize shareholder value.","Options include sale of assets/licensing, collaboration, merger, business combination, or orderly wind-down.","Company to continue evaluating cost-saving measures to preserve cash during the process.","No defined timeline for the review; no assurance any transaction will be consummated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":581596,"accession_number":"0001213900-26-060029","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-05-21T20:01:33+00:00","items":["5.02","9.01"],"status":"ready","headline":"Jasper Therapeutics director Christian Nolet resigns; Svetlana Lucas joins audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christian Nolet resigned from Board and all committees effective May 15, 2026.","Resignation not due to any disagreement with the company's operations, policies or practices.","Board appointed Svetlana Lucas, Ph.D. to the Audit Committee.","No other changes to board composition or officer roles disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442525,"accession_number":"0001213900-26-056596","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-05-14T20:05:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics Q1 net loss $1.2M; refiles Phase 2b protocol for briquilimab in CSU","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents of $14.1M as of March 31, 2026, with $5.8M R&D and $5.1M G&A expenses.","Refiled Phase 2b protocol with FDA for briquilimab in chronic spontaneous urticaria; seeks funding to start H2 2026.","Jeet Mahal appointed CEO to lead next phase of clinical growth.","Positive clinical data: 67% of BEACON patients achieved complete response at 12 weeks; 75% in open-label achieved well-controlled disease.","Median follow-up >200 days; KIT-related AEs low-grade and resolved on study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108567,"accession_number":"0001213900-26-036448","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper posts Q4 net loss $9.1M; cash $28.7M; appoints new CEO; reports positive CSU/asthma data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Jeet Mahal named President and CEO to lead next phase of clinical growth.","Positive CSU data: 67% complete response in BEACON Cohort 9.1; 75% in open-label extension at 12 weeks.","Preliminary asthma data from ETESIAN study shows reduced airway hyperresponsiveness after single 180mg dose.","Internal investigation found no drug product issues; KOL panel recommends enhanced site selection and screening.","Q4 2025 net loss $9.1M; year net loss $75.8M; cash and equivalents $28.7M at Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108566,"accession_number":"0001213900-26-002329","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper reports 67% complete response at week 12 in additional BEACON CSU patients; dose selected for Phase 2b","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["67% (4/6) of new BEACON briquilimab patients achieved complete response at week 12; mean UAS7 drop of 31 points.","In open-label extension, 58% of 36 CSU patients achieved complete response and 75% achieved CR or well-controlled at week 12.","Median follow-up of 205 days in 63 patients; KIT-related AEs were infrequent, low-grade, and resolved without discontinuation.","Company plans to commence Phase 2b study of briquilimab in CSU in second half of 2026.","Briquilimab is an investigational anti-KIT antibody targeting mast-cell-driven diseases like CSU and CIndU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108565,"accession_number":"0001213900-26-002185","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics appoints COO Jeet Mahal as CEO; Ron Martell steps down, Thomas Wiggans named Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Jan 5, 2026, Jeet Mahal becomes CEO and President; he also joins the Board as Class III director.","Outgoing CEO Ron Martell's departure is without cause; he receives 18 months base salary plus COBRA for up to 18 months.","Thomas Wiggans, current Board Chair, appointed Executive Chair effective Jan 5, 2026.","Mahal's annual salary increased to $600,000 with eligibility for performance bonus up to 50% of base salary.","Company to host investor webinar on Jan 8, 2026 to present updated data from BEACON study and open-label extension in CSU/CIndU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125005,"accession_number":"0001213900-25-116943","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper reports positive ETESIAN asthma data; BEACON investigation clears drug product","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single 180mg briquilimab reduced sputum eosinophils from 10.3% to 2.32% at 6 weeks post-allergen challenge.","Late asthmatic response FEV1 AUC improved 25.4% at 6 weeks and 23.3% at 12 weeks vs baseline.","BEACON investigation: no drug product issues; 9 of 10 US patients likely did not have mast cell-driven CSU.","Briquilimab well-tolerated; no dose-limiting toxicities; safety profile consistent with prior studies.","Final BEACON data expected Q1 2026; Phase 2b CSU study planned to start mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125004,"accession_number":"0001213900-25-107874","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Q3 net loss $18.7M; BEACON investigation finds no drug quality issues; cash $50.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.7M ($1.13 per share); R&D expense $14.4M, G&A $4.8M.","Cash $50.9M at Sep 30; completed $30M stock/warrant offering extending runway into H1 2026.","BEACON investigation: no drug substance or product issues; focus now on clinical site processes.","Final BEACON conclusions expected Q4 2025; additional data from BEACON and OLE in H1 Q1 2026 for Phase 2b dose selection.","Initial data from ETESIAN asthma study planned for Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141702,"accession_number":"0001213900-25-089584","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics prices $30M public offering, updates BEACON CSU investigation progress","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$30M from offering of 11.67M shares + warrants at $2.43/share; closing expected Sept 22.","BEACON CSU investigation rules out drug substance/product issues; focus shifts to clinical site activity.","Investigation completion expected in Q4 2025 with KOL panel review for Phase 2b CSU study integration.","Use of proceeds: continued development of briquilimab in mast-cell diseases and general corporate expenses.","Common warrants exercisable at $2.92, 6-month lockout, 4-year term; pre-funded warrants at $0.0001 exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141701,"accession_number":"0001213900-25-075678","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics Q2 net loss $26.7M; cuts workforce 50%, probes BEACON lot issue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.7M ($1.74 per share); cash and equivalents $39.5M as of June 30, 2025.","BEACON study: 89% complete response in 240/360 mg single-dose cohorts; investigation into 240mg Q8W/240/180mg Q8W cohorts due to potential product lot variability.","Workforce reduction of ~50% to focus on urticaria; CMO Dr. Edwin Tucker stepped down, succeeded by Dr. Daniel Adelman as interim.","Halted non-mast cell programs (SCID, asthma ETESIAN study) to concentrate on briquilimab in CSU and CIndU."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141700,"accession_number":"0001213900-25-062194","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["2.05","5.02","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics cuts workforce ~50%, halts non-urticaria programs; CMO departs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~50% and halting of all non-chronic urticaria programs.","Estimated $1.8M-$2.2M in severance cash expenditures through Q3 2025.","CMO Edwin Tucker departs effective Aug 1, 2025; receives 12 months base salary and COBRA.","Dr. Daniel Adelman appointed Acting Chief Medical Officer effective Aug 1, 2025.","Focus on briquilimab in CSU/CIndU; data from BEACON/SPOTLIGHT expected later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141699,"accession_number":"0001213900-25-061632","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper reports 89% complete response in single-dose CSU cohorts, but drug lot issue delays Phase 2b to mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["8 of 9 (89%) patients in 240mg and 360mg single-dose cohorts achieved complete response (UAS7=0).","8 of 11 (73%) in 180mg Q8W open-label extension achieved complete response at week 12.","Results from 240mg Q8W and 240mg→180mg Q8W cohorts confounded by drug product lot issue affecting 10 of 13 patients.","ETESIAN asthma study halted due to same lot issue; SCID development stopped; cost cutting and potential restructuring.","Additional BEACON data expected Q4 2025; Phase 2b CSU study start delayed to mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141698,"accession_number":"0001213900-25-061471","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Jasper Therapeutics shareholders elect directors, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Kurt von Emster, Scott Brun, and Vishal Kapoor as Class I directors with >8.4M votes each.","Ratified PwC as independent auditor for FY 2025: 11,992,658 for, 18,646 against.","Advisory say-on-pay approved: 8,108,299 for, 536,022 against, 9,718 abstentions.","Advisory vote on frequency favored every 1 year (8,580,886 votes); company will hold annual say-on-pay votes.","Turnout ~80% (12,014,527 of 15,022,122 shares represented)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159596,"accession_number":"0001213900-25-054465","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics: 92% complete response in 180mg cohort of briquilimab SPOTLIGHT study in CIndU","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["11 of 12 participants (92%) achieved complete response; 12 of 12 (100%) achieved clinical response within 8-week analysis.","Tryptase levels below lower limit of quantification in 10 of 12 (83%); no SAEs or grade 3+ AEs reported.","Response rapid: 66% achieved CR/PR by week 2; 58% maintained clinical response through week 8.","No hair/skin color changes; mild transient neutrophil drops in 6 of 12 (50%), median resolution 16 days.","Conference call and webinar on June 16, 2025 at 8:00 AM EDT to present data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159595,"accession_number":"0001213900-25-042017","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics Q1 2025 net loss $21.2M; cash $48.8M; briquilimab programs on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.2M ($1.41 per share) for Q1 2025; R&D expenses $16.2M, G&A $5.6M.","Cash and equivalents totaled $48.8M as of March 31, 2025.","BEACON CSU study data (including OLE) expected first half of Q3 2025; Phase 2b planned for H2 2025.","SPOTLIGHT CIndU study full cohort enrolled; additional data at EAACI June 2025.","ETESIAN asthma allergen challenge study enrolling; initial data expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177971,"accession_number":"0001213900-25-025123","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Jasper Therapeutics enters $100M ATM equity offering with Jefferies; terminates prior Cantor agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered Open Market Sale Agreement with Jefferies LLC to sell up to $100M of common stock.","Jefferies will receive 3.0% commission on gross sales price per share; issuer has no obligation to sell.","Prior ATM agreement with Cantor Fitzgerald terminated effective March 14, 2025; no shares sold under it.","Offering will be made under new S-3 registration statement filed March 19, 2025.","No material penalties incurred from termination of Cantor agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177970,"accession_number":"0001213900-25-017656","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics reports FY2024 net loss of $71.3M; briquilimab data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $71.6M at Dec 31, 2024; net loss $71.3M ($4.89 diluted EPS) for FY2024.","BEACON study in CSU: multiple dosing regimens ≥120mg showed >25-point UAS7 improvement; Phase 2b expected H2 2025.","SPOTLIGHT study in CIndU: 14 of 15 patients (93%) achieved clinical response; 83% complete response in 120mg cohort.","First patient dosed in ETESIAN asthma study; initial data expected H2 2025.","Open-label extension study commenced; initial data from ~30 patients expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177969,"accession_number":"0001213900-25-001810","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper reports positive BEACON data: 240mg dose shows UAS7 drop of 26.6, 100% complete response at 8 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean UAS7 change of -26.6 at 8 weeks in 240mg single-dose cohort (N=3); all patients achieved Complete Response (UAS7=0).","Multiple dosing regimens ≥120mg showed UAS7 reduction >25 points; clinical responses as early as 1 week post-first dose.","Serum tryptase reductions below lower limit of quantification observed; 100% of 240mg cohort at week 1.","Favorable safety profile: no dose-limiting toxicities, infrequent low-grade c-Kit blockade events, no discontinuations.","Registrational Phase 2b study in CSU expected to commence in second half of 2025; additional data by mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194671,"accession_number":"0001213900-24-095175","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics Q3 net loss $18.6M, reports positive CIndU data, discontinues LR-MDS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.6M ($1.24 diluted EPS); cash $92.5M at Sept 30, 2024.","SPOTLIGHT study: 93% clinical response (83% complete response) in 120mg cohort; no SAEs.","Initial BEACON data in CSU expected week of Jan 6, 2025; asthma challenge study cleared in Canada/EU.","Discontinued LR-MDS program as briquilimab did not improve hematopoiesis.","R&D expenses $14.5M, G&A $5.4M for Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194670,"accession_number":"0001213900-24-087394","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper reports 93% clinical response rate in SPOTLIGHT study of briquilimab in CIndU","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["14 of 15 patients (93%) achieved clinical response; 10 of 12 (83%) in 120mg cohort had complete response.","No serious adverse events or grade 3+ adverse events reported; well-tolerated with no hair/skin changes.","Initial BEACON study data in CSU expected week of January 6, 2025, including 180mg Q8W cohort.","Regulatory clearance obtained to enroll 180mg dose cohort (n=12) in SPOTLIGHT; full results H1 2025.","Significant tryptase reduction observed (66% at 2 weeks) correlating with clinical responses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229445,"accession_number":"0001213900-24-053982","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics appoints Svetlana Lucas to Board; Anna French resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anna French resigned from Board effective June 18, 2024, citing no disagreement with company.","Svetlana Lucas, Ph.D., appointed as Class III director effective June 18, 2024.","Lucas is Chief Business Officer at Scribe Therapeutics with 20+ years in biopharma strategy.","Received initial option grant of 15,000 shares at $23.19/share, vesting over 4 years.","Also serves on board of aTyr Pharma (Nasdaq: LIFE) and as advisor to Radar Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229444,"accession_number":"0001213900-24-051891","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Jasper Therapeutics stockholders approve 2024 equity plans; amended employment agreements for CEO and other executives","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted 10.3M for, 95K against to approve 2024 Equity Incentive Plan.","Stockholders voted 10.4M for, 12K against to approve 2024 Employee Stock Purchase Plan.","CEO Martell's annual salary remains $727,272; target bonus 50% of base; severance 18 months base plus COBRA.","CFO Cross salary $476,100; COO Mahal $481,301; CMO Tucker $514,500; each target bonus 45% of base.","Company terminated prior severance plan in favor of individual employment agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247999,"accession_number":"0001213900-24-019249","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics reports FY2023 net loss of $64.5M; cash runway through Q3 2025 on $50M Feb 2024 offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023: $64.5M ($6.18 diluted EPS); Q4 net loss $16.6M ($1.50 diluted EPS).","Cash and equivalents $86.9M at Dec 31, 2023; Feb 2024 $50M offering extends runway through Q3 2025.","BEACON Phase 1b/2a in CSU enrolling; initial data from first four cohorts expected Q3 2024.","SPOTLIGHT Phase 1b/2a in CIndU approved; data expected H2 2024.","Phase 1 trial in LR-MDS initiated; initial data anticipated mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247998,"accession_number":"0001213900-24-010267","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics prices $50M underwritten offering of 3.9M shares at $12.95/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$50M from 3,900,000 shares of common stock at $12.95 per share.","Net proceeds to fund clinical development of briquilimab in mast-cell diseases (CSU, CIndU) and general corporate purposes.","Offering expected to close on or about Feb 8, 2024; underwriters include TD Cowen and Evercore ISI.","Directors and executive officers subject to 90-day lock-up expiring May 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247997,"accession_number":"0001213900-24-000980","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Jasper Therapeutics effects 1-for-10 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 12:01 a.m. ET on Jan 4, 2024; shares begin trading split-adjusted same day.","Common stock CUSIP changed to 471871202; trading symbol remains JSPR.","Warrants (JSPRW) adjusted: 10 pre-split warrants exercisable for 1 share at $115.00 exercise price.","No fractional shares issued; cash in lieu paid based on Jan 3, 2024 closing price.","Split approved by board on Dec 22, 2023, after stockholder authorization on Dec 15, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247996,"accession_number":"0001213900-24-000056","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jasper Therapeutics announces 1-for-10 reverse stock split effective Jan 4, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio set at 1-for-10, effective 12:01 a.m. ET on Jan 4, 2024.","Outstanding shares reduced from ~111.6M to ~11.2M; par value unchanged.","Intended to regain compliance with Nasdaq's $1.00 minimum bid price requirement.","No fractional shares; cash in lieu based on Jan 3 closing price.","Warrants adjusted: 10 warrants exercisable for 1 share at $115.00 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265445,"accession_number":"0001213900-23-097100","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Jasper Therapeutics stockholders approve reverse stock split authorization up to 1-for-10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split proposal approved with 91,108,798 votes for, 873,917 against, 32,292 abstentions.","Board may implement split at ratio between 1-for-3 and 1-for-10 at any time before Dec 15, 2024.","Adjournment proposal also approved but was not needed; 91,306,235 votes for, 669,886 against.","Approximately 82% of outstanding shares were represented at the Dec 15 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265444,"accession_number":"0001213900-23-084938","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics reports Q3 2023 net loss of $17.5M; highlights IND clearance for briquilimab in CSU","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.5M ($0.16 per share); R&D expenses $14.8M; G&A expenses $4.5M.","Cash and cash equivalents of $103.9M as of Sept 30, 2023.","FDA cleared IND for Phase 1b/2a study of subcutaneous briquilimab in CSU; first patient expected by end of 2023.","Stanford-sponsored Phase 1/2 study in Fanconi Anemia: all 3 patients achieved full donor engraftment.","Appointed Thomas Wiggans as Chairperson and Herb Cross as CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265443,"accession_number":"0001213900-23-081941","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Jasper appoints Thomas G. Wiggans as Chairperson; William Lis to retire in Dec 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas G. Wiggans joins Board as Class II director and Chairperson effective Nov 1, 2023.","Wiggans, 71, is former CEO/founder of Dermira (acquired by Lilly), ex-CEO of Pardes Biosciences.","Wiggans receives option to purchase 110,000 shares, vesting over 4 years; larger than standard director grant.","William Lis steps down as Chairperson immediately, will resign from Board on Dec 14, 2023 (no disagreement).","Company focuses on briquilimab for mast cell diseases and LR-MDS; initial CSU study launching."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265442,"accession_number":"0001013762-23-005230","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Jasper Therapeutics receives Nasdaq bid price deficiency notice; must regain compliance by Apr 15, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice from Nasdaq: common stock bid price below $1.00 for 30 consecutive business days.","Company has 180 days, until April 15, 2024, to regain compliance with Rule 5550(a)(2).","If bid price closes at $1.00 or more for ten consecutive days, Nasdaq will confirm compliance.","Company may consider a reverse stock split to cure deficiency; no assurance of regaining compliance.","Trading of common stock (JSPR) and warrants (JSPRW) continues on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265441,"accession_number":"0001213900-23-081286","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jasper Therapeutics updates corporate presentation as of October 2023; no specific new data disclosed.","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Furnished updated corporate presentation under Regulation FD; presentation dated October 2023.","Presentation cover slide states Briquilimab is investigational and not approved for any indication.","No financial, clinical, or operational metrics from the presentation are included in the filing.","Company disclaims obligation to update the presentation material in the future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265440,"accession_number":"0001213900-23-081265","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jasper Therapeutics receives FDA IND clearance for Phase 1b/2a study of briquilimab in chronic spontaneous urticaria","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for Phase 1b/2a repeat dose study of subcutaneous briquilimab in CSU patients.","First patient expected by end of 2023; early data from initial cohorts by mid-2024.","Separate CIndU proof-of-concept study to start Q1 2024 with initial data by year-end 2024.","Study enrolls ~40 patients across 6 cohorts; primary endpoints safety/tolerability, secondary efficacy/PK.","Targets CSU patients ineligible for or refractory to omalizumab, a high unmet need population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282649,"accession_number":"0001213900-23-078927","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics appoints Herb Cross as CFO; Jeet Mahal continues as COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Herb Cross, age 51, appointed CFO and Corporate Secretary effective Sept 22, 2023; prior CFO at Atreca.","Cross receives $460k base salary, 45% annual bonus target, $100k sign-on bonus.","Granted option to purchase 550,000 shares at $0.78/share; vests over 4 years (25% cliff at 1 yr, then monthly).","Jeet Mahal transitions from dual CFO/COO role to solely COO.","Option is an inducement grant under Nasdaq Listing Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282648,"accession_number":"0001213900-23-078145","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jasper Therapeutics announces positive Phase 1b data for briquilimab in Fanconi Anemia; all 3 patients engrafted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recovery.","Briquilimab was well tolerated without any complications; no briquilimab-related adverse events or toxicities.","Study expansion to Phase 2a is ongoing, led by Stanford.","Data to be presented at 2023 Fanconi Anemia Research Fund Scientific Symposium (Sept 28-Oct 1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282647,"accession_number":"0001213900-23-066233","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics Q2 2023 net loss $16.1M; cash $115.8M; first patient dosed in LR-MDS trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.1M for Q2 2023 vs $10.4M in Q2 2022; R&D expenses increased to $13.3M from $8.1M.","Cash and cash equivalents $115.8M as of June 30, 2023, up from $38.3M at Dec 31, 2022; runway through 2024.","First patient dosed in Phase 1 trial of briquilimab for lower-risk MDS (LR-MDS) at Moffitt Cancer Center.","Key appointments: Scott Brun to Board, Edwin Tucker as CMO, and others to Scientific Advisory Board and leadership.","Company plans to initiate chronic spontaneous urticaria study in coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301912,"accession_number":"0001213900-23-050029","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Scott Brun, M.D., appointed to Jasper Board as R&D Committee Chair; Klein resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Brun, M.D., appointed as Class I director effective June 20, 2023; chairs R&D Committee, serves on Compensation Committee.","Dr. Brun has over 20 years pharma R&D leadership, including AbbVie, Abbott, and Horizon Therapeutics.","Lawrence Klein, Ph.D., resigned effective June 20, 2023, due to his recent appointment as a Partner at Versant Ventures.","Vishal Kapoor appointed to Audit and Compensation Committees.","Dr. Brun receives initial option grant of 94,000 shares vesting over 4 years under Director Compensation Policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301911,"accession_number":"0001213900-23-047446","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Jasper Therapeutics increases inducement equity plan to 5.5M shares; charter amended for officer exculpation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved amendment to 2022 Inducement Plan, increasing shares from 3M to 5.5M (2.5M new shares).","Amendment adopted without stockholder approval under Nasdaq Rule 5635(c)(4) for inducement awards to new employees.","At June 7 Annual Meeting, stockholders elected Anna French and Judith Shizuru as Class II directors.","Stockholders ratified PricewaterhouseCoopers as independent auditor for FY2023.","Stockholders approved amendment to Certificate of Incorporation for officer exculpation under new Delaware law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301910,"accession_number":"0001213900-23-045834","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics receives FDA guidance for briquilimab in CSU; IND filing and first patient dose expected in H2 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA provided guidance on the proposed program for briquilimab for chronic spontaneous urticaria (CSU).","Company expects to file IND for briquilimab in CSU and dose first patient in H2 2023.","Jasper will continue engagement with FDA toward IND submission and launch of CSU clinical trial.","Updated corporate presentation posted on company website as of June 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301909,"accession_number":"0001213900-23-038997","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics Q1 net loss widens to $14.3M; de-prioritizes AML/MDS Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.3M in Q1 2023 vs $2.2M in Q1 2022, driven by increased R&D and warrant liability changes.","Cash and cash equivalents of $129.4M as of March 31, 2023, boosted by $101.4M net proceeds from January public offering.","De-prioritized Phase 3 development of briquilimab as conditioning for AML/high-risk MDS; now focusing on chronic spontaneous urticaria and low-intermediate risk MDS.","Announced positive clinical data from Phase I/II of briquilimab in sickle cell disease: all three patients engrafted, 100% donor myeloid chimerism at 60 days.","Strengthened board with Vishal Kapoor; appointed Daniel Adelman as Acting CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301908,"accession_number":"0001213900-23-029872","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Jasper Therapeutics adds CEO vesting acceleration, extends chairperson term","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chairperson William Lis term extended to Mar 15, 2024; annual cash comp reduced to $125K from $250K effective Apr 1, 2023.","CEO Ronald Martell: if terminated without cause/good reason within 24 months post-Change in Control, receives 18 months base salary plus full equity vesting.","Change in Control defined by reference to Jasper's Severance Plan; amendments effective April 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321656,"accession_number":"0001213900-23-018537","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics FY2022 net loss $37.7M; expands briquilimab to chronic urticaria, raises $101.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 net loss $37.7M vs $30.6M in 2021; R&D $34.6M, G&A $16.6M.","Cash $38.3M at Dec 31; raised $101.4M net in Jan 2023; expects funding through 2024.","Expanding briquilimab to chronic spontaneous urticaria; 12/12 AML engraftment, 8/12 relapse-free at 1yr.","Appointed Vishal Kapoor to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321655,"accession_number":"0001213900-23-012596","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-02-17T23:59:59+00:00","items":["5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics reports Phase 1 briquilimab data: all 12 patients engrafted; appoints Vishal Kapoor to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Vishal Kapoor to board effective Feb 16, 2023; he is Partner at Avego Management and received option for 109,383 shares at $1.83.","Phase 1 briquilimab data: 12/12 AML patients achieved neutrophil engraftment at median 19 days; no briquilimab-related SAEs.","12 patients at Stanford treated outpatient; all discharged same day (zero inpatient days); mean inpatient stay over first 100 days was 4 days.","Addition of briquilimab to conditioning regimen does not appear to increase GVHD incidence relative to published rates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321654,"accession_number":"0001213900-23-012446","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jasper Therapeutics reports positive briquilimab data: 3 SCD patients achieve 100% donor chimerism","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First two sickle cell disease patients achieved 100% donor myeloid chimerism at Day 100; third at Day 30.","All three patients increased hemoglobin at last follow-up (to 11.4–14 g/dL from baseline 8–10 g/dL).","No graft-versus-host disease or briquilimab-related severe adverse events observed.","Data presented in plenary session at 2023 Tandem Meetings (ASTCT/CIBMTR) on novel antibody-based conditioning.","Study is Phase 1/2 (NCT05357482) evaluating briquilimab as conditioning for bone marrow transplant in SCD and beta thalassemia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321653,"accession_number":"0001213900-23-005582","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics closes $103.5M public offering of 69M shares at $1.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten offering of 69,000,000 shares at $1.50, including 9M option shares.","Gross proceeds of approximately $103.5M before underwriting discounts and expenses.","Offering made under effective shelf registration statement (File No. 333-267777) filed Oct 2022.","Lead book-running managers: Credit Suisse Securities and William Blair; Oppenheimer as passive book-runner.","Company focuses on c-Kit antibody therapies for chronic spontaneous urticaria, MDS, and transplant conditioning."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321652,"accession_number":"0001213900-23-005155","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics prices $90M public offering of 60M shares at $1.50 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 60M shares of common stock at $1.50/share; gross proceeds ~$90M before expenses.","Underwriters granted 30-day option to purchase up to 9M additional shares at same price.","Closing expected on or about Jan 27, 2023; proceeds for general corporate purposes.","Directors and executive officers subject to lock-up agreements until April 25, 2023.","Credit Suisse and William Blair act as active book-running managers; Oppenheimer as passive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321651,"accession_number":"0001213900-23-004843","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jasper Therapeutics posts updated corporate presentation highlighting c-Kit approach and briquilimab","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an updated corporate presentation (Exhibit 99.1) dated January 2023 under Item 7.01.","Presentation titled 'Harnessing the Power of Jasper’s Differentiated c-Kit Therapeutic Approach'.","Briquilimab described as an investigative drug not approved for any indication.","No specific financial or clinical updates provided in the furnished exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321650,"accession_number":"0001213900-23-003597","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Jan 18, 2023 confirming full compliance with Listing Rule 5550(a)(2).","Closing bid price of voting common stock was $1.00 or higher for ten consecutive days (Jan 3-17, 2023).","Compliance removes risk of delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-19T23:59:59+00:00|321650"}